# CMO CDMO Market > CMO/CDMO Market Research Report Information By Service (Contract Development, Contract Manufacturing, and Others), By Product (Hair Products, Skin Products, Lip Products, Eye Products, Body Hygiene, and Oral Hygiene), By Form (Solid Form & Powder, Lotions, Creams, and Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.9% - **2024:** $ 27.08 Billion - **2025:** $ 28.68 Billion - **2035:** $ 50.89 Billion - **Key Players:** Companies such as Lonza (CH), Samsung Biologics (KR), Boehringer Ingelheim (DE), Catalent (US), WuXi AppTec (CN), Fujifilm Diosynth Biotechnologies (JP), Recipharm (SE), Aenova Group (DE), Siegfried (CH) are some of the major participants in the global market. **Report ID:** MRFR/HC/20276-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/cmo-cdmo-market-21874 --- ## Market Summary ## **CMO/CDMO Market Overview** As per MRFR analysis, the CMO/CDMO Market Size was estimated at 27.08 (USD Billion) in 2024. The CMO/CDMO Market Industry is expected to grow from 28.68 (USD Billion) in 2025 to 48.05 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.90% during the forecast period (2025 - 2034). Increased outsourcing of pharmaceutical manufacturing and development activities by pharmaceutical and biotechnology companies are the key market drivers enhancing the market growth. Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ## **CMO/CDMO Market Trends** ### **New-age contract producers strive for greater flexibility and responsiveness**** is driving the market growth.** Market CAGR for CMO/CDMO is being driven by the rising new age contract producers striving for greater flexibility and responsiveness. CMO/CDMO) market, driven by their emphasis on greater flexibility and responsiveness. These emerging players are capitalizing on advancements in technology, process optimization, and supply chain management to offer tailored solutions that meet the dynamic needs of pharmaceutical and biotechnology companies. By prioritizing flexibility, they can swiftly adapt to changes in client requirements, regulatory landscapes, and market demands, enabling seamless integration within the client's value chain. This agility is particularly crucial in the pharmaceutical industry, where rapid shifts in market dynamics, such as changing consumer preferences or emerging therapeutic trends, necessitate quick adjustments in production schedules and formulations. Moreover, the emphasis on responsiveness enables new-age contract producers to establish closer collaborations with their clients, fostering a more symbiotic relationship that transcends traditional vendor-client dynamics. By actively engaging in continuous communication and feedback loops, these CMOs/CDMOs can better understand their clients' evolving needs and proactively propose innovative solutions or process improvements. This collaborative approach not only enhances the quality and efficiency of manufacturing operations but also facilitates knowledge exchange and technology transfer, driving mutual growth and success. Furthermore, growing regulatory complexities and the increasing demand for personalized medicine are further propelling the need for adaptable and agile manufacturing partners. New-age contract producers leverage their expertise in navigating regulatory frameworks and their investment in flexible manufacturing platforms to address these challenges effectively. Whether it's scaling up production to meet surging demand or swiftly pivoting to produce niche therapies, these CMOs/CDMOs are well-positioned to accommodate diverse requirements while maintaining compliance and quality standards. The emphasis on greater flexibility and responsiveness by growing new-age contract producers is a significant driving force behind the expansion of the market. Their ability to adapt quickly, collaborate closely with clients, and navigate regulatory complexities positions them as invaluable partners in the pharmaceutical and biotechnology industries, driving innovation, efficiency, and growth across the value chain. Thus, driving the CMO/CDMO market revenue. ## **CMO/CDMO Market Segment Insights** ### **CMO/CDMO Service Insights** The  CMO/CDMO Market segmentation, based on service, includes Contract Development, Contract Manufacturing, and Others. In 2023, the contract manufacturing segment dominated the market due to its ability to offer flexible and scalable solutions to pharmaceutical and biotechnology companies, allowing them to efficiently meet fluctuating demand and reduce operational costs. By outsourcing manufacturing processes to specialized CMO/CDMO providers, companies can focus on core competencies such as research, development, and marketing while leveraging the expertise and infrastructure of external partners for manufacturing activities. This trend towards outsourcing manufacturing functions has propelled the growth of the contract manufacturing segment within the market, driving innovation and collaboration across the industry. **Figure 1:  CMO/CDMO Market, by Service, 2023 & 2032 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review ### **CMO/CDMO Product Insights** The  CMO/CDMO Market segmentation, based on product, includes Hair Products, Skin products, Lip products, Eye Products, Body Hygiene, and Oral Hygiene. In 2023, the skincare products category will dominate the market due to the high demand for personalized and innovative formulations catering to diverse consumer needs. The skincare industry's continuous pursuit of new ingredients, formulations, and delivery systems necessitates collaboration with CMOs/CDMOs possessing specialized expertise and capabilities. This demand drives substantial outsourcing in the skincare sector as companies leverage the manufacturing proficiency and flexibility offered by CMOs/CDMOs to swiftly bring new products to market while maintaining quality standards. ### **CMO/CDMO Form Insights** The  CMO/CDMO Market segmentation, based on form, includes Solid Form & Powder, Lotions, Creams, and Others. In 2023, the solid & powder category dominated the market due to their widespread applications across various pharmaceutical formulations, including tablets, capsules, and powders for oral administration. These dosage forms offer advantages such as ease of handling, stability, and precise dosing, making them preferred choices for both drug developers and patients. As a result, CMOs and CDMOs specializing in solid form and powder manufacturing play a pivotal role in meeting the industry's demand for high-quality, cost-effective dosage forms. ### **CMO/CDMO Regional Insights** By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American CMO/CDMO market area will dominate this market, owing to a robust pharmaceutical and biotechnology industry, advanced infrastructure, regulatory expertise, and a large pool of skilled professionals. The region's strategic location, coupled with its focus on innovation and quality, positions North American CMOs and CDMOs as preferred partners for companies seeking reliable and high-quality outsourcing services. Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea. **Figure 2:  CMO/CDMO Market Share By Region 2023 (USD Billion)** **** Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review Europe's CMO/CDMO market accounts for the second-largest market share due to the increasing investments in biopharmaceutical research and development. Further, the German CMO/CDMO market held the largest market share, and the UK CMO/CDMO market was the fastest growing market in the European region. The Asia-Pacific CMO/CDMO Market is expected to grow at the fastest CAGR from 2025 to 2034. This is due to increasing investments in healthcare infrastructure, rising pharmaceutical outsourcing activities, lower operational costs, and a growing pool of skilled labor. Moreover, China’s CMO/CDMO market held the largest market share, and the Indian CMO/CDMO market was the fastest growing market in the Asia-Pacific region. ## **CMO/CDMO Key Market Players & Competitive Insights** Leading market players are investing heavily in research and development in order to expand their product lines, which will help the CMO/CDMO market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the CMO/CDMO industry must offer cost-effective items. Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global CMO/CDMO industry to benefit clients and increase the market sector. In recent years, the CMO/CDMO industry has offered some of the most significant advantages to several industries. Major players in the CMO/CDMO market, including Swiss American CDMO, Pierre Fabre Group, Zymo Cosmetics, Fareva, Biofarma Srl C.F., Chemineau, C.O.C. Farmaceutici Srl and Paragon Nordic, and others, are attempting to increase market demand by investing in research and development operations. HK Inno.N Corporation is a leading technology company based in Hong Kong, specializing in innovative solutions across various industries. The company focuses on research and development, particularly in areas such as artificial intelligence, biotechnology, and renewable energy. HK Inno.N Corporation has gained recognition for its cutting-edge products and services, contributing significantly to the advancement of technology in the region. With a strong emphasis on sustainability and efficiency, the company is committed to addressing global challenges through its technological innovations.  Its diverse portfolio includes projects ranging from smart city initiatives to healthcare advancements, demonstrating its versatility and impact on society. HK Inno.N Corporation continues to expand its reach both domestically and internationally, forging partnerships and collaborations to drive further innovation and growth. In May 2022, HK Inno. N Corporation and Dr. Reddy’s Laboratories signed a partnership to supply and commercialize the patented novel molecule Tegoprazan of HK Inno. Corporation for gastrointestinal diseases in India and six important developing markets. Cipla Limited is a renowned Indian multinational pharmaceutical company headquartered in Mumbai, India. It is one of the largest pharmaceutical companies in India, with a strong presence globally. Cipla is known for its wide range of affordable and high-quality generic medicines, covering areas such as respiratory, cardiovascular, anti-retroviral, and oncology drugs. The company has a rich history of innovation and has played a significant role in providing access to affordable healthcare worldwide. In July 2022, Cipla Health Limited, a wholly owned subsidiary and consumer healthcare arm of Cipla Limited, acquired Endura Mass, which is a popular nutritional supplement brand in the weight gain category from Medinnbelle Herbacare Private Limited. ### **Key Companies in the CMO/CDMO Market Include** - Swiss American CDMO - [Pierre Fabre Group](https://www.pierre-fabre.com/en-us/innovation-and-partnerships/partnerships/contract-development-manufacturing) - Zymo Cosmetics - Fareva - Biofarma Srl C.F. - Chemineau - O.C. Farmaceutici Srl - Paragon Nordic ## **CMO/CDMO Industry Developments** **June 2023:** Catalent broadened the scope of its One Bio suite solution, including development, manufacturing, and supply for a range of biotechnological modalities inclusive of recombinant proteins and antibody, cellular and [gene therapy](../../../reports/gene-therapy-market-8399), and also mRNA. **January 2023:** Catalent signed a development and license agreement with Ethican Pharmaceuticals Inc. According to the agreement, Catalent can use its Zydis technology to generate pharmaceutical products containing cannabidiol and tetrahydrocannabinol for Ethican’s use in clinical trials for a variety of conditions. **January 2023**: Thermo Fisher Scientific Inc. acquired Binding Site Group. The Binding Site broadened the already expanded specialized diagnostic range of Thermo Fisher by adding ground-breaking innovation in multiple myeloma diagnosis and monitoring. ## **CMO/CDMO Market Segmentation** ### **CMO/CDMO Service Outlook** - Contract Development - Contract Manufacturing - Others ### **CMO/CDMO Product Outlook** - Hair Products - Skin products - Lip products - Eye Products - Body Hygiene - Oral Hygiene ### **CMO/CDMO Form Outlook** - Solid Form & Powder - Lotions - Creams - Others ### **CMO/CDMO Regional Outlook** **North America** - US - Canada **Europe** - Germany - France - UK - Italy - Spain - Rest of Europe **Asia-Pacific** - China - Japan - India - South Korea - Australia - Rest of Asia-Pacific **Rest of the World** - Middle East - Africa - Latin America ## Market Drivers ### Focus on Cost Efficiency Cost efficiency remains a pivotal driver within the CMO CDMO Market, as pharmaceutical companies seek to optimize their operational expenditures. By outsourcing manufacturing processes to CMOs and CDMOs, companies can significantly reduce capital investments in facilities and equipment. In 2025, it is anticipated that the outsourcing market will grow, with CMOs and CDMOs providing tailored solutions that enhance productivity while minimizing costs.   This trend is particularly pronounced among small to mid-sized pharmaceutical firms that may lack the resources to maintain in-house manufacturing capabilities. The ability to leverage the expertise and infrastructure of CMOs and CDMOs allows these companies to focus on core competencies, thereby fostering innovation and accelerating time-to-market for new drugs. ### Technological Integration The integration of advanced technologies is transforming the CMO CDMO Market, enhancing operational capabilities and efficiency. Innovations such as automation, artificial intelligence, and data analytics are being increasingly adopted by CMOs and CDMOs to streamline manufacturing processes and improve quality control. In 2025, it is projected that the adoption of these technologies will lead to a reduction in production times and costs, while also increasing the accuracy of manufacturing processes.   This technological evolution not only supports the growing demand for personalized medicine but also enables CMOs and CDMOs to meet the stringent regulatory requirements that govern the industry. As a result, companies that embrace these advancements are likely to gain a competitive edge in the market. ### Expansion of Emerging Markets The expansion of emerging markets is significantly influencing the CMO CDMO Market, as pharmaceutical companies seek to tap into new growth opportunities. Regions such as Asia-Pacific and Latin America are witnessing increased investments in healthcare infrastructure and manufacturing capabilities. By 2025, it is anticipated that these emerging markets will contribute substantially to the overall growth of the CMO and CDMO sectors.   The lower operational costs and favorable regulatory environments in these regions make them attractive for outsourcing manufacturing processes. As a result, CMOs and CDMOs are likely to establish strategic partnerships and facilities in these markets, enabling them to cater to the rising demand for pharmaceuticals while enhancing their global footprint. ### Increasing Biopharmaceutical Development The CMO CDMO Market is experiencing a notable surge in biopharmaceutical development, driven by the rising prevalence of chronic diseases and the demand for innovative therapies. As pharmaceutical companies increasingly focus on biologics, the need for specialized contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) has intensified.   In 2025, the biopharmaceutical sector is projected to account for a substantial portion of the overall pharmaceutical market, with estimates suggesting it could reach over 300 billion USD. This growth necessitates the expertise of CMOs and CDMOs to navigate complex manufacturing processes, ensuring compliance with stringent regulatory standards while maintaining efficiency and cost-effectiveness. ### Regulatory Compliance and Quality Assurance Regulatory compliance and quality assurance are critical components driving the CMO CDMO Market. As the pharmaceutical landscape evolves, regulatory bodies are imposing stricter guidelines to ensure the safety and efficacy of drugs. CMOs and CDMOs play a vital role in helping pharmaceutical companies navigate these complex regulations. In 2025, the emphasis on quality assurance is expected to intensify, with CMOs and CDMOs investing in robust quality management systems to meet regulatory standards.   This focus on compliance not only mitigates risks associated with product recalls and legal liabilities but also enhances the reputation of both the CMOs and their clients. Consequently, the ability to demonstrate compliance with regulatory requirements is likely to be a key differentiator in the competitive landscape. ## Future Outlook The CMO/CDMO Market size is projected to reach USD 50.89 billion by 2035, growing at a CAGR of 5.9%, driven by increasing outsourcing and technological advancements. **New opportunities:** - Expansion of biologics manufacturing capabilities Investment in advanced analytics for process optimization Development of sustainable packaging solutions for pharmaceuticals By 2035, the CMO CDMO market is expected to be robust, reflecting strong growth and innovation. ## Segment Insights ### By Application: Pharmaceuticals (Largest) vs. Biotechnology (Fastest-Growing) The applications are predominantly categorized into Pharmaceuticals, Biotechnology, Nutraceuticals, Cosmetics, and Agricultural Chemicals. Pharmaceuticals command the largest CMO CDMO market share at 52% due to the critical demand for contract manufacturing services in drug development and production. With the ongoing advancements in formulations, this segment remains the backbone of contract services, accounting for a significant proportion of market activities. On the other hand, Biotechnology is emerging as a dynamic segment, experiencing rapid growth. This shift is fueled by increasing investments in biopharmaceuticals and innovations in biologic therapies, positioning it as a key driver of industry evolution. Pharmaceuticals (Dominant) vs. Biotechnology (Emerging) The Pharmaceuticals segment within the CMO CDMO market remains dominant, leveraging its extensive experience in handling complex drug formulations and stringent regulatory requirements. It encompasses a wide range of services that support drug development from preclinical stages to commercial production. This dominance is complemented by the increasing complexity of drug types, including generic, branded, and specialty medications. Meanwhile, the Biotechnology segment is characterized by its innovative approach to drug production through biological systems, positioning it as an emerging force. The rise of personalized medicine and biosimilars is expanding its relevance, attracting significant investments and fostering collaborations that enhance capabilities in biologics production. ### By Service Type: Contract Manufacturing (Largest) vs. Contract Development (Fastest-Growing) The service type segment reflects a diverse range of services catering to client needs, with Contract Manufacturing holding the largest CMO CDMO market share of 58% due to its critical role in meeting production demands. Contract Development and other services like Analytical and Packaging Services also contribute significantly, but their shares vary as businesses seek tailored solutions for specific requirements. Contract Manufacturing (Dominant) vs. Contract Development (Emerging) Contract Manufacturing is a crucial player in the CMO CDMO market, providing essential manufacturing capabilities for pharmaceutical companies. This service is pivotal for organizations looking to scale their production without the need for internal capacity investments. On the other hand, Contract Development, although a smaller segment currently, is emerging rapidly as clients increasingly seek customized development solutions to navigate complex regulatory environments and accelerate time-to-market. Both services are vital for fostering innovation within the industry. ### By End Use: Biologics (Largest) vs. Cell and Gene Therapy (Fastest-Growing) The segment showcases a diverse range of end use applications, with biologics leading in CMO CDMO market share 45% due to the increasing demand for therapeutic proteins and monoclonal antibodies. Small molecules, while significant, account for a smaller portion of the total market compared to biologics. Vaccines and peptides are also notable contributors, but the growth of the cell and gene therapy segment is particularly striking as it is revolutionizing treatment options and attracting investment as a breakthrough area of research. Biologics (Dominant) vs. Cell and Gene Therapy (Emerging) Biologics remain the dominant end use segment within the CMO CDMO market, characterized by their established applications in treating chronic diseases and the robust pipeline of innovative products. Monoclonal antibodies and recombinant proteins have become staple therapies, driving consistent demand. In contrast, cell and gene therapy is emerging as a game-changer with potential for personalized medicine, fueling rapid advancements. This segment is marked by its complex manufacturing requirements and an evolving regulatory landscape, which pose challenges yet present significant opportunities for growth as technologies advance and acceptance increases. ### By Product Type: Active Pharmaceutical Ingredients (Largest) vs. Biologics (Fastest-Growing) In the CMO CDMO Market, the product type segment is characterized by a diverse distribution among four key categories: Active Pharmaceutical Ingredients (APIs), Biologics, Small Molecules, and Intermediates. Active Pharmaceutical Ingredients hold a significant share, largely due to their established application in the pharmaceutical industry. In contrast, Biologics have emerged as a crucial segment, reflecting the industry's shift toward advanced therapeutic options. The ongoing demand for innovative treatments is substantially influencing the overall market dynamics. Small Molecules: Dominant vs. Intermediates: Emerging Small Molecules are recognized as a dominant player within the CMO CDMO market. They offer advantages in terms of chemical stability and bioavailability, making them essential for a wide range of therapies. Intermediates, although considered emerging, play a critical role in the pharmaceutical production process. They serve as precursors in the synthesis of APIs, facilitating the creation of complex molecules. The growth of Intermediates is propelled by the increasing demand for custom synthesis and the need for specialized manufacturing capabilities. Together, these segments contribute significantly to the pharmaceutical supply chain, driving innovation and efficiency. ## Regional Market Share Analysis ### North America : Market Leader in CMO CDMO North America continues to lead the CMO CDMO market, holding a significant share of 13.54 in 2024. The region's growth is driven by robust demand for biopharmaceuticals, advancements in manufacturing technologies, and supportive regulatory frameworks. The increasing focus on outsourcing production to enhance efficiency and reduce costs further propels market expansion. Regulatory bodies are actively promoting innovation, which is crucial for maintaining competitive advantages in this dynamic sector. The competitive landscape in North America is characterized by the presence of major players such as Lonza, Catalent, and Boehringer Ingelheim. These companies are investing heavily in R&D and expanding their facilities to meet the growing demand. The U.S. remains a key player, supported by a strong infrastructure and a favorable business environment. The market is expected to continue its upward trajectory as companies leverage technological advancements and strategic partnerships to enhance their service offerings. North America leads due to strong biopharmaceutical demand, advanced manufacturing infrastructure, and outsourcing adoption. High regulatory compliance and R&D investment further accelerate growth. CDC reports over 96% hospital EHR adoption, enabling advanced digital integration supporting pharmaceutical manufacturing efficiency and innovation ecosystems. ### Europe : Emerging Hub for Biotech Europe's market is witnessing significant growth, with a market size of 7.62 in 2024. The region benefits from a strong regulatory framework that encourages innovation and investment in biopharmaceutical manufacturing. Increasing demand for personalized medicine and biologics is driving the need for contract manufacturing services. Additionally, government initiatives aimed at fostering collaboration between academia and industry are catalyzing market growth, making Europe a vital player in the global landscape. Leading countries such as Germany, France, and the UK are at the forefront of this growth, hosting numerous key players like Boehringer Ingelheim and Recipharm. The competitive landscape is marked by strategic partnerships and mergers, enhancing capabilities and service offerings. The European market is characterized by a diverse range of services, from drug development to commercial manufacturing, positioning it as a critical hub for CMO CDMO activities. Europe grows strongly due to biologics demand, regulatory support, and rising personalized medicine adoption. Strong academic-industry collaboration enhances innovation capacity. ECDC highlights over 75% vaccine coverage improvements across multiple EU immunization programs, strengthening biologics manufacturing and CDMO expansion across key markets. ### Asia-Pacific : Rapidly Growing Market The Asia-Pacific region is emerging as a rapidly growing market for CMO CDMO services, with a market size of 4.84 in 2024. This growth is fueled by increasing investments in biopharmaceutical manufacturing, a rising demand for generic drugs, and favorable government policies promoting the biotech sector. The region's diverse population and expanding healthcare needs are driving the demand for contract manufacturing services, making it a focal point for global players looking to expand their footprint. Countries like China, Japan, and South Korea are leading the charge, with significant contributions from companies such as WuXi AppTec and Fujifilm Diosynth Biotechnologies. The competitive landscape is evolving, with local firms increasingly collaborating with international players to enhance capabilities. As the region continues to develop its infrastructure and regulatory frameworks, it is poised for sustained growth in the market. ### Middle East and Africa : Emerging Market Potential The Middle East and Africa (MEA) region is gradually emerging in the market, with a market size of 1.08 in 2024. The growth is driven by increasing healthcare investments, a rising demand for pharmaceuticals, and government initiatives aimed at enhancing local manufacturing capabilities. The region's diverse economic landscape presents unique opportunities for contract manufacturing services, particularly in the biopharmaceutical sector, as countries seek to reduce dependency on imports and build local expertise. Key players are beginning to establish a presence in the region, with countries like South Africa and the UAE leading the way. The competitive landscape is still developing, but there is a growing interest from international firms looking to tap into the potential of the MEA market. As regulatory frameworks improve and infrastructure develops, the region is expected to attract more investments and partnerships in the CMO CDMO space. ## Competitive Benchmarking The CMO CDMO Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for biopharmaceuticals and a growing emphasis on outsourcing manufacturing processes. Key players such as Lonza (CH), Samsung Biologics (KR), and Catalent (US) are strategically positioned to leverage their extensive capabilities in biologics and small molecule production. Lonza (CH) focuses on innovation and capacity expansion, while Samsung Biologics (KR) emphasizes strategic partnerships to enhance its service offerings.   Catalent (US) is actively pursuing digital transformation initiatives to optimize its operations, which collectively shapes a competitive environment that is increasingly reliant on technological advancements and operational efficiency. The market structure appears moderately fragmented, with a mix of large multinational corporations and smaller specialized firms.   Key business tactics such as localizing manufacturing and optimizing supply chains are prevalent among major players, allowing them to respond swiftly to market demands. This collective influence of key players fosters a competitive atmosphere where agility and responsiveness are paramount, enabling firms to capitalize on emerging opportunities in the biopharmaceutical sector.    In November 2025, Lonza (CH) announced the expansion of its biologics manufacturing facility in Switzerland, a strategic move aimed at increasing production capacity to meet the surging demand for monoclonal antibodies. This expansion is likely to enhance Lonza's competitive edge by enabling it to offer more robust solutions to its clients, thereby solidifying its position as a leader in the market. In October 2025, Samsung Biologics (KR) entered into a partnership with a leading biopharmaceutical company to co-develop a new biosimilar product.   This collaboration not only underscores Samsung's commitment to innovation but also reflects a broader trend of strategic alliances within the industry, which may facilitate faster market entry and shared expertise in complex biopharmaceutical development. In September 2025, Catalent (US) launched a new digital platform designed to enhance supply chain visibility and operational efficiency. This initiative is indicative of the growing trend towards digitalization in the market, as companies seek to leverage technology to improve their service offerings and streamline processes, thereby responding to the evolving needs of their clients.   As of December 2025, current competitive trends in the market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. The competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, supply chain reliability, and innovative solutions that meet the complex demands of the biopharmaceutical industry. ## Recent News & Developments **June 2023:** Catalent broadened the scope of its One Bio suite solution, including development, manufacturing, and supply for a range of biotechnological modalities inclusive of recombinant proteins and antibody, cellular and [gene therapy](../../../reports/gene-therapy-market-8399), and also mRNA. **January 2023:** Catalent signed a development and license agreement with Ethican Pharmaceuticals Inc. According to the agreement, Catalent can use its Zydis technology to generate pharmaceutical products containing cannabidiol and tetrahydrocannabinol for Ethican’s use in clinical trials for a variety of conditions. **January 2023**: Thermo Fisher Scientific Inc. acquired Binding Site Group. The Binding Site broadened the already expanded specialized diagnostic range of Thermo Fisher by adding ground-breaking innovation in multiple myeloma diagnosis and monitoring. ## Report Scope | MARKET SIZE 2024 | 27.08(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 28.68(USD Billion) | | MARKET SIZE 2035 | 50.89(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.9% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Lonza (CH), Samsung Biologics (KR), Boehringer Ingelheim (DE), Catalent (US), WuXi AppTec (CN), Fujifilm Diosynth Biotechnologies (JP), Recipharm (SE), Aenova Group (DE), Siegfried (CH) | | Segments Covered | Application, End Use, Service Type, Product Type | | Key Market Opportunities | Integration of advanced biomanufacturing technologies enhances efficiency in the CMO CDMO Market. | | Key Market Dynamics | Rising demand for contract manufacturing services drives competitive dynamics and technological advancements in the CMO CDMO market. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the market as of 2024?** A: The market was valued at 27.08 USD Billion in 2024. **Q: What is the projected market valuation for the CMO CDMO Market in 2035?** A: The market is projected to reach 50.89 USD Billion by 2035. **Q: What is the expected CAGR for the market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 5.9%. **Q: Which segments are included in the CMO CDMO Market by application?** A: The segments by application include Pharmaceuticals, Biotechnology, Nutraceuticals, Cosmetics, and Agricultural Chemicals. **Q: What were the valuation ranges for the Pharmaceuticals segment in 2024?** A: The Pharmaceuticals segment had a valuation range of 10.0 to 18.0 USD Billion in 2024. **Q: Who are the key players in the CMO CDMO Market?** A: Key players include Lonza Group AG, Samsung Biologics, Boehringer Ingelheim, Catalent, WuXi AppTec, Fujifilm Diosynth Biotechnologies, Recipharm AB, Aenova Group, and Siegfried Holding AG. **Q: What services are categorized under the CMO CDMO Market by service type?** A: Services include Contract Manufacturing, Contract Development, Process Development, Analytical Services, and Packaging Services. **Q: What is the projected valuation for the Biologics segment in 2035?** A: The Biologics segment is projected to reach a valuation of 12.0 USD Billion by 2035. **Q: What were the valuation ranges for the Peptides segment in 2024?** A: The Peptides segment had a valuation range of 8.08 to 15.89 USD Billion in 2024. **Q: How does the CMO CDMO Market's growth compare across different end-use segments?** A: The end-use segments include Small Molecules, Biologics, Cell and Gene Therapy, Vaccines, and Peptides, each showing varied growth potential. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cmo-cdmo-market-21874*